. . . . "At present, there has been no experience with overdose. Single doses of up to 1000 mg of oseltamivir have been associated with nausea and/or vomiting. Mean LD (intravenous, mouse) = 100 mg/kg."@en . . . . . "1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-"@en . . "Agucort"@en . "Readily absorbed from the gastrointestinal tract after oral administration with a bioavailability of 75%."@en . . . "Oseltamivir"@en . . . "Influenza Virus"@en . . . . . . . . "(\u2212)-oseltamivir"@en . . "* 23 to 26 L"@en . . . . . "Tamiflu"@en . . . . . . "Oseltamivir carboxylate: low (3%), Oseltamivir free base: 42%."@en . "\"DrugSyn.org\":http://www.drugsyn.org/Oseltamivir.htm"@en . "(-)-Oseltamivir"@en . "approved"@en . "GS-4104"@en . "# Chokephaibulkit K, Uiprasertkul M, Puthavathana P, Chearskul P, Auewarakul P, Dowell SF, Vanprapar N: A child with avian influenza A (H5N1) infection. Pediatr Infect Dis J. 2005 Feb;24(2):162-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15702046 # de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J: Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005 Dec 22;353(25):2667-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16371632 # Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004 Aug 28-Sep 3;364(9436):759-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15337401 # Ward P, Small I, Smith J, Suter P, Dutkowski R: Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005 Feb;55 Suppl 1:i5-i21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15709056"@en . "HSDB 7433"@en . . " "@en . . "Oseltamivir is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. The proposed mechanism of action of oseltamivir is inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release."@en . "Take without regard to meals. Food may improve gastric tolerance."@en . . . . . . . "Oseltamivirum"@en . . . " "@en . . "Oseltamivir"@en . . "Absorbed oseltamivir is primarily (>90%) eliminated by conversion to oseltamivir carboxylate. Oseltamivir carboxylate is not further metabolized and is eliminated in the urine. Oseltamivir carboxylate is eliminated entirely (>99%) by renal excretion."@en . . "204255-11-8"@en . . . . . . . . . . . . . "An acetamido cyclohexene that is a structural homolog of sialic acid and inhibits neuraminidase. [PubChem]"@en . . . . . "Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate"@en . . . . . . . . "1 to 3 hours in most subjects after oral administration."@en . . "Oseltamivir (Tamiflu) is for the treatment of uncomplicated acute illness due to influenza infection in patients 1 year and older who have been symptomatic for no more than 2 days. It is also used for the prophylaxis of influenza in adult patients and adolescents 13 years and older."@en . . . . . .